726 related articles for article (PubMed ID: 18248643)
1. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
3. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin.
Guido M; Romualdi D; De Marinis L; Porcelli T; Giuliani M; Costantini B; Lanzone A
Fertil Steril; 2007 Jul; 88(1):125-30. PubMed ID: 17276431
[TBL] [Abstract][Full Text] [Related]
4. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
5. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome.
Zwirska-Korczala K; Sodowski K; Konturek SJ; Kuka D; Kukla M; Brzozowski T; Cnota W; Woźniak-Grygiel E; Jaworek J; Bułdak R; Rybus-Kalinowska B; Fryczowski M
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():161-78. PubMed ID: 18812636
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
7. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
8. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
Wang A; Li M; Lu C
Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
[TBL] [Abstract][Full Text] [Related]
9. [Serum levels of ghrelin and leptin in women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Orbtsova M; Terzieva D
Akush Ginekol (Sofiia); 2008; 47(3):15-9. PubMed ID: 18756827
[TBL] [Abstract][Full Text] [Related]
10. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
14. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome.
Moran C; Renteria JL; Moran S; Herrera J; Gonzalez S; Bermudez JA
Fertil Steril; 2008 Dec; 90(6):2310-7. PubMed ID: 18163993
[TBL] [Abstract][Full Text] [Related]
15. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
[TBL] [Abstract][Full Text] [Related]
16. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
17. Elevated ghrelin plasma levels in patients with polycystic ovary syndrome.
Waśko R; Komarowska H; Warenik-Szymankiewicz A; Sowiński J
Horm Metab Res; 2004 Mar; 36(3):170-3. PubMed ID: 15057670
[TBL] [Abstract][Full Text] [Related]
18. Hormonal levels of leptin, insulin, ghrelin, and neuropeptide Y in lean, overweight, and obese Saudi females.
Daghestani MH; Ozand PT; Al-Himadi AR; Al-Odaib AN
Saudi Med J; 2007 Aug; 28(8):1191-7. PubMed ID: 17676200
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
Romualdi D; Costantini B; Campagna G; Lanzone A; Guido M
Fertil Steril; 2008 Nov; 90(5):1826-33. PubMed ID: 18166189
[TBL] [Abstract][Full Text] [Related]
20. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
